Updated:
Aisling Capital
Aisling Capital is a leading investment firm that invests in products, technologies, and global businesses that advance health. Since 2000, Aisling Capital has...
Aisling Capital
Aisling Capital is a leading investment firm that invests in products, technologies, and global businesses that advance health. Since 2000, Aisling Capital has raised over $1.8 billion in committed capital across four funds. Aisling Capital invests in both private and public companies utilizing a wide variety of investment structures. The firm's team combination of clinical, operational and financial experience allows it to identify, execute and realize investments across the life sciences industry.
General information
Firm type
Private Equity
Year founded
2000
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, United States
Principals
Steven Elms
Managing Partner
Andrew Schiff
MD, Managing Partner
Eric Aguiar
MD, Partner
Sunny Reddy
Principal
Wonpyo Yun
Principal
Robert Wenzel
Chief Financial Officer and Chief Compliance Officer
Katie Tansey
Vice President of Investor Relations and Marketing
Hannah Wieder
Controller
Carol Zikopoulos
Head of Human Resources and Compliance Manager
Dr. Josh Bilenker
Operating Partner
Scott Braunstein
MD, Operating Partner
Aftab Kherani
MD, Operating Partner
Sector focus
Frequently asked questions
What strategies does Aisling Capital pursue?
Records list buyout, divestiture, early-stage seed and start-up, expansion, growth, PIPE, private-to-public, spin-offs, and general venture.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: